Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19

Guan WJ et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. https://doi.org/10.1056/NEJMoa2002032

Zhou P et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270–273

Vankadari N, Wilce JA (2020) Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect 9(1):601–604

Qi F et al (2020) Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun 526(1):135–140. https://doi.org/10.1016/j.bbrc.2020.03.044

Raj VS et al (2013) Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495(7440):251–254

Lambeir AM et al (2003) Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40(3):209–294

Lei Y et al (2017) Dipeptidyl peptidase-IV inhibition for the treatment of cardiovascular disease- recent insights focusing on angiogenesis and neovascularization. Circ J 81(6):770–776

Nistala R, Savin V (2017) Diabetes, hypertension, and chronic kidney disease progression: role of DPP4. Am J Physiol Renal Physiol 312(4):F661–F670

Slimane TA et al (2000) Apical secretion and sialylation of soluble dipeptidyl peptidase IV are two related events. Exp Cell Res 258(1):184–194

Cuchacovich M et al (2001) Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. Clin Exp Rheumatol 19(6):673–680

Lu G et al (2013) Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500(7461):227–231

Waumans Y et al (2015) The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis. Front Immunol 6:387

Schon E et al (1984) Dipeptidyl peptidase IV of human lymphocytes. Evidence for specific hydrolysis of glycylproline p-nitroanilide in T-lymphocytes. Biochem J 223(1):255–258

Durinx C et al (2000) Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 267(17):5608–5613

Schade J et al (2008) Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats. J Histochem Cytochem 56(2):147–155

Meyerholz DK, Lambertz AM, McCray PB Jr (2016) Dipeptidyl peptidase 4 distribution in the human respiratory tract: implications for the middle east respiratory syndrome. Am J Pathol 186(1):78–86

Zaki AM et al (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367(19):1814–1820

Wronkowitz N et al (2014) Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2. Biochim Biophys Acta 1842(9):1613–1621

Drosten C et al (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348(20):1967–1976

Kuiken T et al (2003) Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362(9380):263–270

Channappanavar R, Perlman S (2017) Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 39(5):529–539

Channappanavar R et al (2016) Dysregulated Type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe 19(2):181–193

Guo YR et al (2020) The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. Mil Med Res 7(1):11

Loretelli C et al (2020) Embryonic stem cell extracts improve wound healing in diabetic mice. Acta Diabetol. https://doi.org/10.1007/s00592-020-01500-0

Fiorina P et al (2004) Normalization of multiple hemostatic abnormalities in uremic type 1 diabetic patients after kidney-pancreas transplantation. Diabetes 53(9):2291–2300

D’Addio F et al (2015) Circulating IGF-I and IGFBP3 levels control human colonic stem cell function and are disrupted in diabetic enteropathy. Cell Stem Cell 17(4):486–498

Astorri E et al (1997) Isolated and preclinical impairment of left ventricular filling in insulin-dependent and non-insulin-dependent diabetic patients. Clin Cardiol 20(6):536–540

Kleine-Weber H et al (2020) Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus. Emerg Microbes Infect 9(1):155–168

Hopsu-Havu VK, Glenner GG (1966) A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie 7(3):197–201

Klemann C et al (2016) Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system. Clin Exp Immunol 185(1):1–21

Trzaskalski NA, Fadzeyeva E, Mulvihill EE (2020) Dipeptidyl peptidase-4 at the interface between inflammation and metabolism. Clin Med Insights: Endocrinol Diabetes 13:1179551420912972

Ling J et al (2019) The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials. Acta Diabetol 56(3):249–272

Ling J et al (2019) DPP-4 inhibitors for the treatment of type 2 diabetes: a methodology overview of systematic reviews. Acta Diabetol 56(1):7–27

Morimoto C, Schlossman SF (1998) The structure and function of CD26 in the T-cell immune response. Immunol Rev 161:55–70

Huhn J et al (2000) Molecular analysis of CD26-mediated signal transduction in T cells. Immunol Lett 72(2):127–132

Vora KA et al (2009) Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses. BMC Immunol 10:19

Kruschinski C et al (2005) CD26 (dipeptidyl-peptidase IV)-dependent recruitment of T cells in a rat asthma model. Clin Exp Immunol 139(1):17–24

Ikeda T et al (2013) Soluble CD26/dipeptidyl peptidase IV enhances the transcription of IL-6 and TNF-alpha in THP-1 cells and monocytes. PLoS ONE 8(6):e66520

Pedersen SF, Ho YC (2020) SARS-CoV-2: a storm is raging. J Clin Invest. https://doi.org/10.1172/JCI137647

Al-Qahtani AA et al (2017) Middle east respiratory syndrome corona virus spike glycoprotein suppresses macrophage responses via DPP4-mediated induction of IRAK-M and PPARgamma. Oncotarget 8(6):9053–9066

Lee YS et al (2012) Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia 55(9):2456–2468

Lee YS, Jun HS (2016) Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators Inflamm. https://doi.org/10.1155/2016/3094642

Cheng XW et al (2018) Dose rectification of an imbalance between DPP4 and GLP-1 ameliorates chronic stress-related vascular aging and atherosclerosis? Clin Exp Pharmacol Physiol 45(5):467–470

Kawasaki T et al (2018) DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol 315(5):L834–L845

Xu J et al (2018) Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension. Lab Invest 98(10):1333–1346

Deacon CF, Lebovitz HE (2016) Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab 18(4):333–347

Deacon CF (2019) Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of Type 2 diabetes. Front Endocrinol (Lausanne) 10:80